Sugi Predict

Sugi Predict / Compounds / SCHEMBL84546

SCHEMBL84546

SCHEMBL84546

Brc1cnc(-c2ccccc2)o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.59
▸ ALOX15 P16050 1/20 0.59
▸ CASP1 P29466 1/20 0.59
▸ RAB9A P51151 10/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ MITF O75030 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ NPC1 O15118 9/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.48
▸ KDM4E B2RXH2 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ HPGD P15428 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ PTPN1 P18031 2/20 0.45
▸ TP53 P04637 3/20 0.44
▸ LMNA P02545 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26684345 0.77 NPC1 (0.53) TSHRRAB9AMITFNPC1SMN1; SMN2
SCHEMBL74359 0.76 ALOX15 (0.96) TSHRALOX15CASP1RAB9AMEN1
SCHEMBL10595737 0.76 TSHR (0.61) TSHRALOX15CASP1RAB9AMEN1
SCHEMBL12102873 0.75 CYP4F2 (0.43) TSHRALOX15CASP1RAB9AMEN1
SCHEMBL24670073 0.75 KDM4E (0.45) TSHRALOX15CASP1RAB9AMEN1
SCHEMBL69417 0.75 NPC1 (0.46) RAB9ANPC1SMN1; SMN2KDM4EALDH1A1
SCHEMBL28161163 0.75 TSHR (0.82) TSHRALOX15CASP1RAB9AMEN1
SCHEMBL28411650 0.75 TSHR (0.82) TSHRALOX15CASP1RAB9AMEN1
SCHEMBL28710167 0.75 TSHR (0.82) TSHRALOX15CASP1RAB9AMEN1
SCHEMBL5154252 0.74 ALOX15 (0.59) TSHRALOX15CASP1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3623372-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH INC (US) 2026-02-04 — — EP disclosed
WO-2025264954-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-12-26 — — WO disclosed
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use AMGEN INC. (US) 2025-11-18 — — US disclosed
WO-2025149498-A1 BENZYLPIPERIDINE DERIVATIVES AS TRP4 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ASTRAZENECA AB (SE) 2025-07-17 — — WO disclosed
US-20240293381-A1 Therapeutic Compounds CELGENE QUANTICEL RES INC (US) 2024-09-05 — — US disclosed
US-20240252655-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS NOVARTIS AG (CH) 2024-08-01 — — US disclosed
WO-2024133292-A1 NOVEL CCR8 ANTAGONISTS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-27 — — WO disclosed
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors VALO HEALTH, INC. (US) 2024-06-25 — — US disclosed
CN-114025847-B Compounds and compositions as modulators of TLR signaling 神经孔疗法股份有限公司 2024-05-24 — — CN disclosed
WO-2024097355-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS VICINITAS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
WO-2009115572-A2 NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF NOVARTIS AG (CH) 2009-09-24 — — WO disclosed
US-7405299-B2 Compounds as pharmaceutical agents ELI LILLY AND COMPANY (US) 2008-07-29 — — US disclosed
US-7119201-B2 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC (US) 2006-10-10 — — US disclosed
US-20060058295-A1 Novel compounds as pharmaceutical agents ELI LILLY AND COMPANY (US) 2006-03-16 — — US disclosed
EP-1501515-B1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PROD INC (US) 2005-11-02 — — EP disclosed
EP-1567527-A1 CONDENSED PYRAZOLO DERIVATIVES ELI LILLY AND COMPANY (US) 2005-08-31 — — EP disclosed
EP-1501515-A1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-02 — — EP disclosed
WO-2004050659-A1 NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS ELI LILLY AND COMPANY (US) 2004-06-17 — — WO disclosed
US-20040006057-A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER PRODUCTS INC. 2004-01-08 — — US disclosed
WO-2003090752-A1 TRIARYL-OXY-ARYLOXY-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252655-A1 DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS USP2, USP1, USP28 TSHR 3797/4885ALOX15 4661/4885CASP1 809/4885
US-20060058295-A1 Novel compounds as pharmaceutical agents TGFB1, TGFB2, TGFBR1 TSHR 1511/4885ALOX15 3572/4885CASP1 2227/4885
US-20240293381-A1 Therapeutic Compounds EP300, BRD4, BRD3 TSHR 4134/4885ALOX15 3505/4885CASP1 1876/4885
US-20040006057-A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP8, MMP9, MMP1 TSHR 1833/4885ALOX15 244/4885CASP1 75/4885
US-12018030-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors USP7, UBA7, UBXN1 TSHR 3130/4885ALOX15 4129/4885CASP1 396/4885
US-12473289-B2 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use SCD5, SCD, FADS2 TSHR 2532/4885ALOX15 41/4885CASP1 3145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.